Trials / Available
AvailableNCT07380165
Expanded Access Program (EAP) of Levacetylleucine for Ataxia-Telangiectasia (A-T)
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- IntraBio Inc · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
This expanded access program provides investigational levacetylleucine to patients with Ataxia-Telangiectasia who are not eligible for clinical trials and have no satisfactory alternative therapies.
Detailed description
This expanded access program provides access to investigational drug, levacetylleucine, for eligible patients with Ataxia-Telangiectasia that are not eligible for other clinical trials, and a medical doctor has decided there is potential benefit outweighing the risk of receiving an investigational therapy based on the patient's medical history and program eligibility criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levacetylleucine | 1 gram levacetylleucine as granules in unit-dose packet. Investigational drug is administered as oral suspension, up to three times per day, based on body weight. |
Timeline
- First posted
- 2026-02-02
- Last updated
- 2026-02-24
Source: ClinicalTrials.gov record NCT07380165. Inclusion in this directory is not an endorsement.